I agree with you. I believed (and still do) in A-block as a great product and the benefits of anatabine. I invested a large amount in STSI but have sold practically all of it at a great loss because I have deep concerns about the stock.
Firstly the cash flow situation looks quite awful. In order to survive, it will have to raise money and dilute sooner or later. The other alternative is to be bought for a pittance relative to its potential worth. A-block is just not selling well enough to overcome these cash problems.
Secondly, management is awful. It did a terrible job on the tobacco side, inspite of winning. Remember the fiasco concerning the mistakes in the initial press release of the results of one of the studies last year? This is one of the most investor-unfriendly stocks in the marketplace. It doesn't hold any conference calls for the public, but only for a select few investors. The marketplace, probably quite rightly, does not trust JW.
Thirdly, I really do think that STSI is on to something regarding anatabine and its role in controlling NFkB. In fact, so much that big-pharma is likely to do anything in its immense power to kill it.
I will continue to keep a close watch on this stock, if the three things mentioned above improve, I will become more interested as an owner.
